Document Detail


Characterization of in vitro biotransformation of the new oral anticoagulants, the factor VIIa inhibitors AS1927819-00 and AS1932804-00.
MedLine Citation:
PMID:  23875246     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
We recently developed a prodrug (AS1932804-00, CMP) of the novel FVIIa inhibitor AS1924269-00, which possesses a carbamate amidine backbone. In addition, we developed another type of prodrug (AS1927819-00, OXP) with an oxime amidine backbone. In this study, we investigated the efficiency of conversion of these novel FVIIa prodrugs to their active forms by evaluating the production of the active form in vitro by using microsomes, mitochondria, and cryopreserved hepatocytes, and compared it with the in vivo conversion mechanisms of the prodrugs (oxime amidine vs. carbamate amidine). We observed that OXP and CMP showed improved oral absorption, and the efficiency of conversion of CMP to the active form was higher than that of OXP. The in vivo rate of conversion of OXP to its active form was low in rats, and compared to liver microsomes and mitochondria, cryopreserved hepatocytes supplemented with serum and coenzymes were an appropriate metabolic test tool. On the other hand, the efficiency of conversion of CMP to its active from could be appropriately evaluated using small intestinal microsomes. The development of a prodrug can be optimized when information about the stability of carboxylic acid esters in the presence of serum esterases, membrane permeability of intermediate forms, and differential tissue specificity to metabolic activities for carbamate and oxime backbones of amidine can be obtained.
Authors:
T Nakabayashi; Y Gotoh; N Kamada; M Fujioka; T Ishihara; A Hirabayashi; H Sato
Related Documents :
24233806 - Influence of urea and organic solvents on the activity of immobilizedmyo-inositol-1-pho...
23325926 - Implication of indolamine 2,3 dioxygenase in the tolerance toward fetuses, tumors, and ...
24386096 - Isolation and characterization of a novel endoglucanase from a bursaphelenchus xylophil...
24845646 - 3d restoration microscopy improves quantification of enzyme-labeled fluorescence-based ...
18604506 - Characterization of the bacillus subtilis wl-3 mannanase from a recombinant escherichia...
8652966 - Recurrent reversible rhabdomyolysis associated with hyperthermia and status epilepticus.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Die Pharmazie     Volume:  68     ISSN:  0031-7144     ISO Abbreviation:  Pharmazie     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-07-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9800766     Medline TA:  Pharmazie     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  406-13     Citation Subset:  IM    
Affiliation:
Pharmacokinetics Research Laboratories, Kissei Pharmaceutical Co., Ltd., 19-48 Yoshino, 399-8710 Matsumoto-City, Nagano-Pref, Japan. takeshi_nakabayashi@pharm.kissei.co.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Preparation, characterization and in vitro release study of gallic acid loaded silica nanoparticles ...
Next Document:  Metabolism of fenofibrate in beagle dogs: new metabolites identified and metabolic pathways revealed...